Clinical trial: Adjuvant tamoxifen may reduce recurrence risk for patients with ‘good-risk’ DCIS who forgo radiation

by

For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the same breast, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10–13, 2024.

Leave A Comment

Your email address will not be published. Required fields are marked *